The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) is a huge mover today! The stock decreased 6.36% or $3.53 during the last trading session, hitting $52. About 619,033 shares traded hands or 21.04% up from the average. SAGE Therapeutics Inc (NASDAQ:SAGE) has risen 51.02% since April 14, 2016 and is uptrending. It has outperformed by 46.33% the S&P500.
The move comes after 5 months negative chart setup for the $1.97B company. It was reported on Nov, 16 by Barchart.com. We have $48.36 PT which if reached, will make NASDAQ:SAGE worth $137.90M less.
SAGE Therapeutics Inc (NASDAQ:SAGE) Ratings Coverage
Out of 10 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 8 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 80% are positive. SAGE Therapeutics has been the topic of 11 analyst reports since September 3, 2015 according to StockzIntelligence Inc. JP Morgan maintained the stock with “Buy” rating in Thursday, September 3 report. On Tuesday, May 24 the stock rating was initiated by Chardan Capital Markets with “Sell”. The firm earned “Buy” rating on Monday, November 14 by Stifel Nicolaus. The firm has “Neutral” rating given on Wednesday, March 30 by Goldman Sachs. On Tuesday, September 13 the stock rating was initiated by Raymond James with “Outperform”. Leerink Swann maintained the stock with “Buy” rating in Thursday, September 3 report. The stock has “Outperform” rating given by BMO Capital Markets on Wednesday, June 29. The stock of SAGE Therapeutics Inc (NASDAQ:SAGE) earned “Buy” rating by Lake Street on Friday, March 11. As per Thursday, June 23, the company rating was initiated by H.C. Wainwright.
According to Zacks Investment Research, “SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1.51 in Q2 2016. Its down 0.73, from 2.24 in 2016Q1. The ratio turned negative, as 28 funds sold all SAGE Therapeutics Inc shares owned while 27 reduced positions. 23 funds bought stakes while 60 increased positions. They now own 29.30 million shares or 2.83% more from 28.49 million shares in 2016Q1.
Tiaa Cref Invest Mngmt Lc holds 88,521 shares or 0% of its portfolio. Group Incorporated One Trading Lp last reported 5,700 shares in the company. Great West Life Assurance Communication Can holds 0% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE) for 4,162 shares. Moreover, Blackrock Group has 0% invested in SAGE Therapeutics Inc (NASDAQ:SAGE) for 63,550 shares. Wells Fargo Communication Mn last reported 27,266 shares in the company. Opaleye Mngmt Inc accumulated 1.7% or 125,000 shares. Los Angeles Capital Mngmt And Equity Rech has 6,890 shares for 0% of their US portfolio. Jefferies Gp Limited Liability Com reported 43,110 shares or 0.01% of all its holdings. Gilder Gagnon Howe And Com has invested 0.19% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). Brown Brothers Harriman And Company holds 92 shares or 0% of its portfolio. Ameriprise Financial last reported 0% of its portfolio in the stock. Wexford L P last reported 30,396 shares in the company. Citadel Advsrs Ltd Liability Corp reported 650,008 shares or 0.02% of all its holdings. Deutsche National Bank & Trust Ag accumulated 0.01% or 417,012 shares. Proshare Advsrs Llc owns 27,110 shares or 0.01% of their US portfolio.
Insider Transactions: Since July 12, 2016, the stock had 0 insider buys, and 4 insider sales for $1.31 million net activity. Shares for $880,000 were sold by Robichaud Albert on Tuesday, July 12. IGUCHI KIMI also sold $102,325 worth of SAGE Therapeutics Inc (NASDAQ:SAGE) on Wednesday, September 7.
More notable recent SAGE Therapeutics Inc (NASDAQ:SAGE) news were published by: Fool.com which released: “Here’s Why SAGE Therapeutics Inc. Is Surging Today” on July 12, 2016, also Prnewswire.com with their article: “Sage Therapeutics, Inc. – Product Pipeline Review – 2016” published on September 27, 2016, Valuewalk.com published: “SAGE Therapeutics Inc (SAGE) – Debunking Asclepia Capital” on April 01, 2016. More interesting news about SAGE Therapeutics Inc (NASDAQ:SAGE) were released by: Marketwatch.com and their article: “Sage Therapeutics shares surge 45% on positive trail of postpartum depression drug” published on July 12, 2016 as well as Seekingalpha.com‘s news article titled: “Sage Therapeutics, Inc: Overhyped Lead Drug Headed For Failure” with publication date: March 23, 2016.
SAGE Company Profile
SAGE Therapeutics, Inc., incorporated on April 16, 2010, is a clinical-stage biopharmaceutical company. The Firm is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also targets the GABAA receptor system. The Firm is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.